Vertex, Kymera join forces for developing protein degradation drugs
Category: #health  By Nikita Chaurasia  Date: 2019-05-17
  • share
  • Twitter
  • Facebook
  • LinkedIn

Vertex, Kymera join forces for developing protein degradation drugs

Vertex would be paying $70 million in advance to work with Kymera including an equity investment in the company

Kymera Therapeutics and Vertex Pharmaceuticals Incorporated (VRTX) have reportedly announced that they are entering into a four-year research and development partnership to discover and develop small molecule protein degraders against various targets.

Sources close to the matter mentioned that the partnership will leverage Kymera’s expertise in its proprietary Pegasus™ drug discovery platform and in targeted protein degradation and Vertex’s clinical, scientific, and regulatory capabilities. It will boost the development of first in class medicines for people suffering from serious diseases.

According to Senior Vice President and Site Head of Boston Research at Vertex, Mark Bunnage, this partnership with Kymera Therapeutics will improve the company’s drug discovery capabilities and reinforce the approach of investing in scientific innovation to develop transformative drugs for serious diseases.

As per the terms of the four-year deal, Vertex would be paying $70 million in advance to work with Kymera including an equity investment in the company. Under the collaboration, Kymera will conduct research activities in several targets. Once a clinical development candidate is selected, Vertex has the option to completely license molecules against the selected target.

On the other hand, Kymera is also eligible to receive over $1 billion in potential payments based upon the successfully achieving research, development, commercial, and regulatory milestones for up to six programs optioned as part of the partnership, sourced mentioned.

President and CEO of Kymera Therapeutics, Dr. Laurent Audoly, Ph.D., said that this strategic partnership will widen the application of targeted protein degradation for addressing serious diseases having limited or no treatment options.

For the uninitiated, Kymera Therapeutics is a biotechnology company pioneering a new and transformative approach towards treating serious diseases which were previously untreatable. The company advances in the field of targeted protein degradation and disease-causing proteins to tackle substantial unmet medical need.

 

Source Credit: https://finance.yahoo.com/news/vertex-kymera-therapeutics-establish-strategic-123000590.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Syndax Pharmaceuticals reveals data from phase 1 trial of axatilimab
Syndax Pharmaceuticals reveals data from phase 1 trial of axatilimab
By Nikita Chaurasia

According to reliable sources, Massachusetts-headquartered clinical stage biopharmaceutical company, Syndax Pharmaceuticals Inc. has revealed an updated data from its Phase 1 trial of its patent axatilimab. The company will reportedly present the dat...

Xiaomi shares drop by 7.1% after raising USD 3.9 billion in equity deal
Xiaomi shares drop by 7.1% after raising USD 3.9 billion in equity deal
By Nikita Chaurasia

Shares of Xiaomi Corporation, a Chinese multinational electronics company, witnessed a 7.1% drop during Hong Kong trading after the company secured USD 3.91 billion in fund raising which also included the city’s top-up placement. The company h...

Supercom signs a supply contract of PureSecurity EM suite in Wisconsin
Supercom signs a supply contract of PureSecurity EM suite in Wisconsin
By Nikita Chaurasia

Israel-based leading provider of advanced solutions for cybersecurity, IoT (Internet of Things) and e-Government sectors Supercom has reportedly signed a supply agreement to deliver its PureSecurity EM (Electronic Monitoring) product suite in Wiscons...